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Introduction. We report a rare presentation of Castleman’s disease in a hepatitis C-positive patient and present a short review of
treatments described in other similar case reports and studies. Case Presentation. A 46-year-old male with untreated hepatitis C
and a 16-year history of intravenous drug use presented with pleuritic chest pain and bony pain in the knee, hip, and lower back,
on a background of unexplained weight loss of 40 kilograms, fevers, night sweats, and repeated infections over the last two years.
Examination discovered tender hepatomegaly, a warm right knee effusion, and painless lymphadenopathy. The patient was reactive
to Epstein Barr virus and cytomegalovirus; however, HIV and HHV-8 viral testing was negative. Osteomyelitis of vertebrae T8–
T11 and septic arthritis of the knee were found on investigation. A lymph node biopsy revealed histology suggestive of plasmacytic
Castleman’s disease. The patient is to commence rituximab treatment. Conclusion. Castleman’s disease continues to present in
novel ways, which may lead to difficulties in clinicopathologic diagnosis. A growing body of evidence suggests larger studies are
required to determine the best treatment for multicentric Castleman’s disease, particularly in patients with a concomitant disease,
including hepatitis C.
1. Introduction
Castleman’s disease, formally known as angiofollicular lym-
phoid hyperplasia, is a term given to a group of disorders
characterised by lymph node hyperplasia—a result of abnor-
mal proliferation of B lymphocytes and plasma cells.
Since its initial discovery by Benjamin Castleman in
1956, few cases of this disease have been reported. Given the
rarity of the disease within the population, exact statistics
on incidence and prevalence are not well known. However,
from observation of case studies, it appears that the localised
unicentric form ofCastleman’s disease ismore prevalent than
the multicentric type [1].
The aetiopathological association between multicentric,
plasmacytic Castleman’s disease and human herpesvirus 8
(HHV-8) is well known [1]. However, the exact cause of
Castleman’s disease remains speculative. Current theories
include (1) a response to chronic nonspecific inflammatory
processes, (2) stimulation from chronic viral infections, such
as HIV, Epstein Barr virus, and HHV-8, (3) angiogenic
factors leading to the characteristic increased vascularity in
Castleman’s disease histology, and (4) cytokine stimulation
resulting in plasma cell proliferation [1].
Both clinical and histopathological classifications exist
for Castleman’s disease. Clinically, Castleman’s disease is clas-
sified into unicentric and multicentric types. Unicentric
Castleman’s disease (UCD) generally presents with a solitary
slow-growing lymph node in the mediastinum, without
elevation of interleukin-6 (IL-6) and C-reactive protein
(CRP). Because unicentric Castleman’s disease lacks the
release of inflammatory mediators, presentation of the
disease is mainly due to mass effect of the lesion. In contrast,
multicentric Castleman’s disease (MCD) is characterised
by widespread lymphadenopathy with or without hep-
atomegaly, and with an elevation of acute phase reactants IL-
6 and CRP. Thus, MCD may present with additional consti-
tutional symptoms including fever, hepatomegaly, anaemia,
weight loss, and loss of appetite, primarily through the action
of IL-6 [2]. Lymphoproliferation generally localises in the
mediastinum and lung hila; however, cases of extrathoracic
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distribution have been documented in a number of sites,
including the parotid glands, retroperitoneum, and eye
[3–5].
Histologically, there are three classifications of Castle-
man’s disease. Hyaline vascular type shows poorly formed,
dysplastic lymph node germinal centres of CD21+ dendritic
cells, with outer concentric layers of CD20+ lymphocytes,
and associated vascularity and hyperplasia of endothelium.
Plasmacytic type, in comparison, presents with layers of
plasma cells in the interfollicular areas, with a larger mantle
zone. The mixed variant is a combination of the aforemen-
tioned histological types. Interestingly, the hyaline vascular
type is more commonly seen in UCD, and plasmacytic type
is more commonly seen in MCD [6].
From the limited data available, the prognosis appears
positive for UCD but poor for MCD [7]. MCD may
exist as benign disease, or premalignant disease which may
transform into Hodgkin’s lymphoma—a marker of poorer
outcome [8].
2. Case Presentation
A 46-year-old man presented to the emergency department
with pleuritic chest pain, a swollen and painful right knee,
and weight-bearing difficulty. Accompanying this was hip
and back pain after a fall. This occurred on a background of
unexplained progressive weight loss of 40 kilograms over the
past 2 years, poor appetite, fever and drenching night sweats,
increased susceptibility to infection, and intravenous drug
use. He had a 16-year history of hepatitis C (HCV; genotype
3), which remained untreated due to noncompliance and
poor clinic attendance. He had been a well-built professional
boxer of 96 to 100 kilograms for most of his adult life;
however, his admission weight was 60.61 kilograms. This was
a loss of approximately 63% of his total body weight. His
relevant medical history includes postoperative pulmonary
embolism, disc prolapse, mild depression, and a family
history of adult polycystic kidney disease. The relevant
surgical history includes osteomyelitis and amputation of the
third digit of the right hand, and multiple fracture repairs.
Systems review was unremarkable. He has a complicated
social history including a troubled upbringing, intravenous
heroin use up to 1 gram per day, experimentation with most
illicit drugs, a significant criminal history, and participation
in an opiate substitution programme. He does not smoke
tobacco or drink alcohol.
On examination, the patient appeared acutely unwell,
although vital signs were normal. He appeared cachectic, had
sunken eyes, reduced skin turgor, poor dentition, extensive
tattoos, and had track marks in the cubital fossae and groin.
There was rib and mediastinal tenderness with no masses.
Right upper quadrant abdominal tenderness was noted on
palpation, with hepatomegaly 6 centimetres below the costal
margin. Nontender lymphadenopathy was present in the
upper left jugular nodes and bilaterally in the groin. A warm,
right knee effusion was also apparent. There were no signs
suggestive of infective endocarditis or chronic liver disease.
Respiratory, cardiovascular, thyroid, and neurological exam-
inations were unremarkable.
Initial blood biochemistry revealed a noncritical normo-
cytic normochromic anaemia (haemoglobin 102 g/L), raised
CRP, elevated calcium (2.57mmol/L), and low albumin
(23 grams/L). A thyroid function test detected 18 picomols/L
of free T4 (normal range 7–17 pmols/L). This was assumed
to be a transient reactive elevation rather than the cause
of such significant weight loss. Liver function tests, blood
cultures, electrolytes, renal function, coagulation profile,
α-fetoprotein, vasculitic screen, iron studies, vitamin B12,
urate, and globulins were all within normal ranges. Hep-
atitis C serology was reactive with an IgG response. forth
generation antigen/antibody assay was performed twice, four
weeks apart, to determine HIV positivity; however, both
tests returned negative. The patient’s history revealed that
previous HIV tests were also negative, and as such a Western
blot analysis was not performed. Hepatitis B serology was
consistent with immunisation. Polymerase chain reaction
found the patient to be reactive to cytomegalovirus (CMV),
and Epstein Barr virus (EBV), but human herpes virus 8
was not detected. Although blood IL-6 levels could have
been used as a marker of systemic inflammation, C-reactive
protein was chosen instead as per hospital policies. A
computerized tomography of the chest and abdomen found
enlarged para-aortic lymph nodes and lytic lesions in T8 and
T9. There was no splenomegaly, and the liver architecture
was unchanged.
A computerized tomography pulmonary angiogram,
chest X-ray, and cardiac troponin I were requested to exclude
pulmonary embolism, rib fracture and pneumothorax, and
myocardial infarction. All were normal. The right knee joint
was aspirated, and fluid analysis showed methicillin sensitive
Staphylococcus aureus which was treated as septic arthritis
with intravenous flucloxacillin and vancomycin. Following
spiking fevers over the next few weeks in hospital, a tran-
soesophageal echocardiogram was performed to exclude
infective endocarditis from a septic arthritis-induced bacter-
aemia.
At this point, the patient was clinically suspected to have
lymphoma or multiple myeloma, and further investigations
undertaken were to exclude either. β-2 microglobulin and
LDH levels were normal, no monoclonal band was detected
on serum and urine protein electropheresis, and flow
cytometry showed normal subpopulations of B cell and T cell
lineages. A bone scan showed further destructive thoracic
lesions but did not confirm its extent. Magnetic resonance
imaging confirmed T8 to T11 osteomyelitis with epidural
involvement indenting on, but not compressing, the spinal
cord. Lymphoma and multiple myeloma were excluded by
bone marrow biopsy.
The diagnosis of multicentric plasmacytic Castleman’s
disease was histologically confirmed by an excision biopsy
from an inguinal lymph node.Macroscopically, the specimen
was a circumscribed ovoid nodulemeasuring 30×22×10mm
with a central blackish area. Microscopically, no malignant
cells, Reed Sternberg cells, or their variants were seen. This
was confirmed by two separate laboratories. Also noted were
distinct hyaline deposits, prominent paracortical expansion
by sheets of plasma cells, and subcapsular and interfollicular
neutrophilic bodies. HHV-8 was not detected in this sample.
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A four-week rituximab regime was chosen as the primary
treatment for this patient. Steroid treatment was also being
considered as adjunct therapy.
3. Discussion
This case report of multicentric Castleman’s disease high-
lights a number of emerging diagnostic and management
issues with this condition. This patient was negative for
both HIV and HHV-8, which emphasises the importance
of including MCD as a differential diagnosis in a patient
who presents with lymphadenopathy and constitutional
symptoms, despite lacking two major aetiological risk factors
for the disease. Even with histological evidence, the diagnosis
of MCD remains inaccurate; clinicopathologically, MCD
may present very similarly to other lymphoproliferative
disorders [9], and as such, the presence of MCD as a separate
clinical entity must always be considered.
In addition to diagnostic difficulties, this case under-
scores the growing need for randomised trials for sug-
gested treatments in Castleman’s disease, and to develop a
clearer indication of the efficacy of each treatment regimen.
A number of curative therapies for MCD are currently avail-
able and have demonstrated definite clinical improvement
and remission. These include cytoreductive chemotherapy,
immune modulators including steroids and interferon-α,
and monoclonal antibodies anti-IL-6 and rituximab (for full
review, see [1]). However, each has only been evidenced in
few case reports, and as such the exact efficacy and use in
specific clinical scenarios requires elucidation.
The use of rituximab has been recommended for use in
HIV- and HHV-8-negative patients [1]; however, no studies
have investigated its role in HCV-positive cases. No clear
guidelines have been made with regards to treatment of
MCD in cases with associated active hepatitis C. Three
previous case reports discuss presentations of concomitant
treated HCV and MCD [10–12]. Interestingly, in one case
report, interferon-α, a treatment drug for hepatitis C, was
also successfully implemented as long-term therapy for
concomitant MCD [12]. Although this initially led to the
idea of a possible causative relationship between MCD and
HCV, two separate case studies have shown promising results
of interferon-α for MCD even in HCV- negative patients
[13, 14].
There is evidence to suggest an association between HCV
and MCD, and this may be mediated by the cytokine IL-
6. IL-6, as regarded in current aetiopathological theories
of MCD, is thought to stimulate plasma cell proliferation.
Untreated HCV often results in a systemic inflammatory
state; this may be responsible for elevated IL-6 which could
be a contributing factor to the development of MCD. The
existence of such a link in further research may introduce
the possibility for novel uses of hepatitis C treatment as
adjunct therapy for combined cases of hepatitis C and MCD.
Irrespective of whether this causation exists, we speculate
that, although not utilised in this patient, use of interferon-α
therapy in cases of concomitant hepatitis C and MCD may
be a useful treatment for future similar cases.
4. Conclusion
This case report contributes to a growing body of evidence
which demonstrates the need for further study into manage-
ment options for virus-associated multicentric Castleman’s
disease. We conclude that future research directions should
be aimed at clarification of guidelines for existing manage-
ment of MCD and, additionally, to determine a possible
aetiopathological association between HCV and MCD.
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